Glucantime (Meglumine Antimonate)

Glucantime is indicated for the systemic treatment of leishmaniasis caused by various Leishmania species.

• Cutaneous leishmaniasis in adults.
• Mucocutaneous leishmaniasis when systemic therapy is required.
• Visceral leishmaniasis (kala-azar) as part of combination regimens.
• Cases where alternative antimonial agents are contraindicated.
• Post‑exposure prophylaxis in endemic regions under specialist guidance.

Adverse reactions to Glucantime vary in frequency and severity; patients should be monitored throughout therapy.

Common

• Injection site pain or erythema.
• Nausea or vomiting.
• Transient fever or chills.

Serious

• Cardiac arrhythmias.
• Severe pancreatitis.
• Hematologic abnormalities (e.g., neutropenia).

Before initiating Glucantime, clinicians should evaluate patient history and laboratory values to reduce the risk of complications.

• Baseline cardiac assessment (ECG) is recommended.
• Liver and renal function tests should be performed prior to and during treatment.
• Monitor complete blood count for signs of bone‑marrow suppression.
• Use with caution in patients with pre‑existing cardiac disease.
• Avoid in individuals with known hypersensitivity to antimonial compounds.
• Pregnancy and breastfeeding status should be assessed; benefits must outweigh risks.

Glucantime may interact with other medicines; understanding potential interactions helps maintain safety and efficacy.

Avoid

• Concomitant use of cardiotoxic drugs (e.g., quinidine, amiodarone) that may exacerbate arrhythmias.
• Concurrent administration of nephrotoxic agents (e.g., aminoglycosides) that could worsen renal impairment.

Use with caution

• Drugs affecting hepatic metabolism (e.g., azole antifungals) may alter liver enzyme levels.
• Immunosuppressants (e.g., corticosteroids) may mask infection signs.
• Other antimonial preparations, to prevent cumulative toxicity.